In this phase @ trial , we randomly assigned @ previously untreated patients who had unresectable stage IIIC or stage IV melanoma with a BRAF V@E or V@K mutation to receive a combination of dabrafenib ( @ mg orally twice daily ) and trametinib ( @ mg orally once daily ) or dabrafenib and placebo .